Results 81 to 90 of about 2,139,344 (395)
A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression‐free survival
Molecular Oncology, EarlyView.There is an unmet need in metastatic breast cancer patients to monitor therapy response in real time. In this study, we show how a noninvasive and affordable strategy based on sequencing of plasma samples with longitudinal tracking of tumour fraction paired with a statistical model provides valuable information on treatment response in advance of the ...Emma J. Beddowes, Mario Ortega Duran, Solon Karapanagiotis, Alistair Martin, Meiling Gao, Riccardo Masina, Ramona Woitek, James Tanner, Fleur Tippin, Justine Kane, Jonathan Lay, Anja Brouwer, Stephen‐John Sammut, Suet‐Feung Chin, Davina Gale, Dana W. Y. Tsui, Sarah‐Jane Dawson, Nitzan Rosenfeld, Maurizio Callari, Oscar M. Rueda, Carlos Caldas +20 morewiley +1 more sourceEscape from TGF‐β‐induced senescence promotes aggressive hallmarks in epithelial hepatocellular carcinoma cells
Molecular Oncology, EarlyView.Chronic TGF‐β exposure drives epithelial HCC cells from a senescent state to a TGF‐β resistant mesenchymal phenotype. This transition is characterized by the loss of Smad3‐mediated signaling, escape from senescence, enhanced invasiveness and metastatic potential, and upregulation of key resistance modulators such as MARK1 and GRM8, ultimately promoting Minenur Kalyoncu, Dilara Demirci, Sude Eris, Bengisu Dayanc, Ece Cakiroglu, Merve Basol, Merve Uysal, Gulcin Cakan‐Akdogan, Fang Liu, Mehmet Ozturk, Gökhan Karakülah, Serif Senturk +11 morewiley +1 more sourceSiPMs coated with TPB: coating protocol and characterization for NEXT [PDF]
Journal of Instrumentation, 2012 Submitted to the Journal of Instrumentation on december 26th ...Álvarez Puerta, Vicente, Agramunt, J., Ball, M., Batallé, M., Bayarri, J., Borges, Filipa I.G.M., Bolink, H., Brine, H., Cárcel García, Sara, Carmona, J.M., Castel, J., Catalá, J.M., Cebrián, Susana, Cervera Villanueva, Anselmo, Chan, D., Conde, Carlos A.N., Dafni, Theopisti, Dias, T.H.V.T, Díaz Medina, José, Esteve, Raúl, Evtoukhovitch, P., Ferrando, J., Fernandes, L.M.P., Ferrario, Paola, Ferreira, Antonio Luis, Ferrer-Ribas, E., Freitas, Elisabete D.C., García, S.A., Gil Ortiz, Alejandro, Giomataris, I., Goldschmidt, Azriel, Gómez, E., Gómez, H., Gómez Cadenas, Juan José, González, K., Gutiérrez, Rafael María, Hauptman, John M., Hernando Morata, J.A., Herrera, D.C., Herrero, Vicente, Iguaz, F.J., Irastorza, Igor Garcia, Kalinnikov, V., Labarga, Luis A., Liubarsky, Igor, Lopes, J.A.M., Lorca Galindo, David, Losada, Marta, Luzón, Gloria, Marí, A., Martín-Albo Simón, Justo, Méndez, A.M., Miller, Tom P., Moiseenko, A., Monrabal Capilla, Francesc, Monteiro, Cristina M.B., Monzó, J.M., Mora, Francisco José, Muñoz Vidal, J., Natal da Luz, H., Navarro, G., Nebot Guinot, Miquel, Nygren, David R., Oliveira, Carlos A.B., Palma, R., Pérez Aparicio, J.L., Pérez, Javier Martin, Radicioni, E., Quinto, M., Renner, Joshua, Ripoll Masferrer, Lluís, Rodríguez, Ángel Y., Rodríguez Samaniego, Javier, Santos, Filomena P., dos Santos, Joaquim M.F., Seguí, Laura, Serra Díaz-Cano, Luis, Shuman, Derek B., Sofka, C., Sorel, Michel, Soriano, A., Spieler, H., Toledo, J.F., Torrent Collell, Jordi, Tomás, A., Tsamalaidze, Zviadi, Vázquez, D., Velicheva, E., Veloso, João F.C.A., Villar, José Ángel, Webb, R.C., Weber, T., White, James T., Yahlali Haddou, Nadia +93 moreopenaire +7 more sourcesShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling
Molecular Oncology, EarlyView.We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones +11 morewiley +1 more sourceTargeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model
Molecular Oncology, EarlyView.Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker +19 morewiley +1 more sourceInhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry
Molecular Oncology, EarlyView.Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder +11 morewiley +1 more sourceAberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu +12 morewiley +1 more sourceRoom temperature-curable, easily degradable, and highly malleable and recyclable vanillin-based vitrimers with catalyst-free bond exchange
Polymer Testing, 2022 Development of bio-based vitrimers attracted significant attention due to these species’ excellent recyclability and renewability. However, most bio-based vitrimers require high-temperature curation and catalyst use.Min Liu, Fei Gao, Xinru Guo, Qianqian Liang, Jinlong He, Jiang Zhong, Cong Lin, Faman Lin, Liang Shen +8 moredoaj Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman +17 morewiley +1 more source
